News

News and Press Releases
About the CF Foundation | Our Research Approach Cystic Fibrosis Foundation Announces Investment in SalioGen Therapeutics to Fund Genetic Therapies Research

Investment will support discovery research of a novel Gene CodingTM approach that could benefit all people with CF regardless of their mutation
 

| 5 min read
About the CF Foundation | Clinical Trials | Our Research Approach CF Foundation Awards Up to $5 Million to BiomX for Potential Phage Therapy

Study reaffirms the Foundation’s commitment to advance solutions to the growing challenge of antibiotic resistance

| 4 min read
Research | About the CF Foundation | Our Research Approach CF Foundation Awards Contract to Life Edit Therapeutics to Explore Gene Editing Technology in CF

Today, the Cystic Fibrosis Foundation announced that it has awarded up to $400,000 to Life Edit Therapeutics Inc. to explore the application of their unique gene editing technology in CF.

| 3 min read
Research | About the CF Foundation CF Foundation Commits up to $14 Million in Funding to Expand Research Agreement With Synspira Therapeutics

New funding will support clinical development of two novel therapies to address complications of cystic fibrosis

| 3 min read
Coronavirus (COVID-19) | Our Research Approach First Global Study of COVID-19 in Children With Cystic Fibrosis Reports Reassuring Outcomes

The Cystic Fibrosis Registry Global Harmonization Group, including the Cystic Fibrosis Foundation, published findings from the first global study on the impact of COVID-19 on children with cystic fibrosis in the Journal of Cystic Fibrosis.

| 4 min read
Antibiotics | Advocacy The Cystic Fibrosis Foundation Affirms Support of the Introduction of the PASTEUR Act

Proposed legislation has the potential to revitalize the global marketplace for novel antibiotics, bringing urgently needed medicines for drug-resistant infections to patients.

| 2 min read
Research | About the CF Foundation | Clinical Trials CF Foundation Awards Up to $2M to Eloxx for Additional Support for Studies into Nonsense Mutations Therapy

Today, the Cystic Fibrosis Foundation announced a new award of up to $2 million to Eloxx Pharmaceuticals Inc. to support the global Phase 2 clinical program of ELX-02, a potential therapy to treat people with cystic fibrosis who have nonsense mutations.

| 4 min read
Clinical Trials First-of-Its-Kind Study Uses Smartphone to Track Cystic Fibrosis in Real Life

Observational study supported by the CF Foundation will monitor real-world experience with Trikafta

| 4 min read
Research | About the CF Foundation | Our Research Approach CF Foundation Awards Up to $2.17 Million to Beyond Air® to Develop Portable NTM Treatment

Today, the Cystic Fibrosis Foundation announced that it has awarded up to $2.17 million to Beyond Air® to support the development of a portable inhaled nitric oxide treatment for nontuberculous mycobacteria, difficult-to-treat bacteria that infect the lungs of people with cystic fibrosis.

| 4 min read